Conditions: Chronic Kidney Disease
Keywords: Chronic kidney disease Vitamin D Paricalcitol Placebo Kidney Renal Oxidative Stress Immune cell function Glucose Glucose tolerance
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 22
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD).

Detailed description:
Persons with chronic kidney disease (CKD) are at markedly increased risk of death, particularly from cardiovascular disease (CVD). A number of metabolic abnormalities may contribute to adverse health outcomes in CKD, including glucose intolerance, altered immune cell function, and oxidative stress. Each of these metabolic stressors is a known complication of CKD. Since these metabolic abnormalities are also known to contribute to the pathogenesis of cardiovascular disease, they are important potential therapeutic targets in CKD.

This study will test whether oral paricalcitol, an active form of vitamin D, will improve glucose tolerance, immune cell function, and reduce oxidative stress in people with stage 3-4 chronic kidney disease.

Arms:
arm 1: Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks. arm 2: Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.

Interventions: intervention 1: Paricalcitol intervention 2: Placebo
Intervention descriptions: intervention 1: Two 1 mcg soft gels by mouth daily for 8 weeks intervention 2: Two soft gels by mouth daily for 8 weeks

Protocol document: